A study from Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA. & Functional Genomics of Cancer Unit, Division of Molecular Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy shows that Rescue of Hippo coactivator YAP1 triggers DNA damage–induced apoptosis in hematological cancers. This study was published in the May, 2014 Nature Medicine by Dr Francesca C & Dr. Giovanni Tonon, Harvard Medical School, Boston; and Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan.
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: MiRNA-based Cancer therapy: miRNA-18a increases the transcriptional activity of tumor suppressor p53 homologue p73 via down regulation of its target gene. This data suggest that miR-18a, by suppressing the expression of its down steam target gene, it will increase the transcriptional activity of tumor suppressor p73 in a cell context dependent manner. Given that tumor suppressor p53 is mutated in about 50% of different human cancers, this study suggests, for the first time, a therapeutic strategy as to how mutant p53 expressing human cancer can be cured by activating its un-mutated homologous proteins.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, MiRNA-based Cancer therapy: miRNA-18a increases the transcriptional activity of tumor suppressor p53 homologue p73 via down regulation of its target gen, 14/May/2014, 13.30, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
